Dexmedetomidine has a possible protective effect on cardiac surgery-associated acute kidney injury (CSA-AKI); however, current evidence is limited and controversial. We therefore conducted a meta-analysis regarding dexmedetomidine for CSA-AKI.

PubMed and EMbase were searched. A random-effects model in RevMan 5.3 software was used, and *P* \< 0.05 indicates statistical significance. Three randomized controlled trials (RCTs) with 338 patients and four cohort studies involving 19,266 participants were included. The main characteristics are shown in Table [1](#Tab1){ref-type="table"}. Overall results show that dexmedetomidine was associated with a significantly reduced incidence of CSA-AKI in both the RCTs (relative risk \[RR\] 0.44, 95% confidence interval \[CI\] 0.26--0.76, *p* = 0.003) and cohort studies (RR 0.74, 95% CI 0.63--0.86, *p* = 0.0001) (Fig. [1](#Fig1){ref-type="fig"}) without significant heterogeneity (RCT *I* ^*2*^ = 0%; cohort *I* ^*2*^ = 0%). For secondary outcomes, dexmedetomidine failed to decrease postoperative mortality (RCT RR 0.20, 95% CI 0.02--1.68; cohort RR 0.56, 95% CI 0.28--1.15), duration of mechanical ventilator (RCT standard mean differences \[SMD\] −0.18, 95% CI −2.08--1.71; cohort SMD −0.12, 95% CI −0.25--0.01), intensive care unit stay (RCT SMD −0.21, 95% CI −0.53--0.11; cohort SMD −0.52, 95% CI −1.06--0.02), and hospital length of stay (SMD −0.34, 95% CI −1.21--0.54). However, decreased trends were observed for all secondary outcomes.Table 1Main characteristic of the seven included studiesStudyIDStudy typeNumber (DEX/Control)Surgery typeInterventionRef (DOI)DEXControlAmmar et al. 2016 \[[@CR4]\]RCT25/25Cardiac surgery with CPB5 min before CPB until 6 h after surgery (1 μg/kg for 15 min and followed by 0.5 μg/kg/h)Placebo10.4103/1658-354X.177340Balkanay et al. 2015 \[[@CR2]\]RCT60/28CABG with CPBAfter ICU admission and continuing for a maximum of 24 h (0.04 μg/kg/h to 0.5 μg/kg/h)Placebo10.1093/icvts/ivu367Cho et al. 2015 \[[@CR5]\]RCT100/100Cardiac surgery with CPBAfter anesthetic induction and continuing for 24 h after surgery (0.4 μg/kg/h)Placebo10.1038/ki.2015.306Ji et al. 2013 \[[@CR3]\]Cohort (retrospective)567/566CABG/valve surgery with CPBAfter CPB and continuing for a maximum of 24 h (0.24 μg/kg/h to 0.6 μg/kg/h)Control10.1371/journal.pone.0077446Kwiatkowski et al. 2016Cohort (retrospective)102/102Cardiac surgery with CPBNRControl10.1097/PCC.0000000000000611Shehabi et al. 2012Cohort (prospective)76/77Cardiac surgery with CPBAfter anesthetic induction and until extubation (0.7 μg/kg/h)Control10.1097/01.ccm.0000425199.76669.9fTuran et al. 2014Cohort (retrospective)765/17,011Cardiac surgeryNRControl10.1016/j.jclinane.2014.05.009*CABG* coronary artery bypass graft, *CPB* cardiopulmonary bypass, *DEX* dexmedetomidine, *ICU* intensive care unit, *NR* not reported, *RCT* randomized controlled trial Fig. 1Forest plots for the meta-analysis of dexmedetomidine and the incidence of CSA-AKI

A retrospective cohort study \[[@CR1]\] and an RCT \[[@CR2]\] were not consistent with the other included studies in our meta-analysis. This inconsistency could be explained by limitations of retrospective studies, different CSA-AKI criteria, different doses and duration of dexmedetomidine for the cohort, and CSA-AKI criteria for the RCT because the preventive effect was found when defined by NGAL concentration but not RIFLE classification.

The underlying mechanism is multifactorial, and current evidence demonstrates that, as a selective α2-adrenoreceptor agonist, the renoprotective function of dexmedetomidine could be achieved by promoting renal blood flow via inhibiting vasoconstriction and promoting a diuresis effect via decreasing renin and arginine vasopressin and increasing glomerular filtration \[[@CR3]\]. Additionally, protection from kidney ischemia/reperfusion injury by reducing reactive oxygen species, decreased systemic inflammatory response, and reduced renal cell death in cardiac surgery were also involved \[[@CR4]\].

Hypotension and bradycardia caused by dexmedetomidine are often of concern, mainly with loading and maintenance doses \>0.7 μg/kg/h \[[@CR5]\]. All reported dexmedetomidine doses were lower than 0.7 μg/kg/h in our meta-analysis except for two unknown cohorts. Additionally, dexmedetomidine's safety and efficacy have been confirmed in cardiac surgery \[[@CR1]\].

In summary, dexmedetomidine might be a promising prevention strategy for CSA-AKI. More high-quality RCTs are encouraged to verify the beneficial effect of dexmedetomidine before its clinical application.

CI

:   Confidence interval

CSA-AKI

:   Cardiac surgery-associated acute kidney injury

ICU

:   Intensive care unit

RCT

:   Randomized controlled trial

RR

:   Relative risk

SMD

:   Standard mean difference

None.

Funding {#FPar1}
=======

Cultivation Fund of The First Affiliated Hospital of Chongqing Medical University (PYJJ2017-12).

Availability of supporting data {#FPar2}
===============================

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

RS and HTT conceived the study, participated in the design, and collected the data. HTT performed statistical analyses. RS drafted the manuscript. HTT revised the manuscript critically for important intellectual content. Both authors read and approved the final manuscript.

Authors' information {#FPar3}
====================

HTT is now working as a cardiothoracic surgeon in the Department of Cardiothoracic Surgery, The First Affiliated Hospital of Chongqing Medical University. HTT is also the young editor of the *Chinese Journal of Clinical Thoracic and Cardiovascular Surgery* and section editor of the *Journal of Emergency and Critical Care Medicine*. His major research interests include evidence-based medicine, critical care medicine, ischemia-reperfusion injury, and perioperative organ protection.

Ethics approval and consent to participate {#FPar4}
==========================================

Not applicable.

Consent for publication {#FPar5}
=======================

Not applicable.

Competing interests {#FPar6}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar7}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
